244 related articles for article (PubMed ID: 23892273)
1. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Wang X; Li JP; Yang Y; Ding J; Meng LH
Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
[TBL] [Abstract][Full Text] [Related]
2. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.
Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D
FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732
[TBL] [Abstract][Full Text] [Related]
4. Better Understanding of Phosphoinositide 3-Kinase (PI3K) Pathways in Vasculature: Towards Precision Therapy Targeting Angiogenesis and Tumor Blood Supply.
Tsvetkov D; Shymanets A; Huang Y; Bucher K; Piekorz R; Hirsch E; Beer-Hammer S; Harteneck C; Gollasch M; Nürnberg B
Biochemistry (Mosc); 2016 Jul; 81(7):691-9. PubMed ID: 27449615
[TBL] [Abstract][Full Text] [Related]
5. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.
Shugg RP; Thomson A; Tanabe N; Kashishian A; Steiner BH; Puri KD; Pereverzev A; Lannutti BJ; Jirik FR; Dixon SJ; Sims SM
J Biol Chem; 2013 Dec; 288(49):35346-57. PubMed ID: 24133210
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
7. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Van Dort ME; Jang Y; Bonham CA; Heist K; Palagama DSW; McDonald L; Zhang EZ; Chenevert TL; Luker GD; Ross BD
Eur J Med Chem; 2022 Feb; 229():113996. PubMed ID: 34802837
[TBL] [Abstract][Full Text] [Related]
8. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
Jude JA; Tirumurugaan KG; Kang BN; Panettieri RA; Walseth TF; Kannan MS
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):427-35. PubMed ID: 22556157
[TBL] [Abstract][Full Text] [Related]
9. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
10. PI3K signalling in inflammation.
Hawkins PT; Stephens LR
Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Stamatkin C; Ratermann KL; Overley CW; Black EP
Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
[TBL] [Abstract][Full Text] [Related]
12. Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors.
Song D; Tang L; Wang L; Huang J; Zeng T; Fang H; Wang X
Cell Biol Toxicol; 2020 Feb; 36(1):51-64. PubMed ID: 31522336
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Yea SS; So L; Mallya S; Lee J; Rajasekaran K; Malarkannan S; Fruman DA
PLoS One; 2014; 9(6):e99486. PubMed ID: 24915189
[TBL] [Abstract][Full Text] [Related]
14. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
15. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
[TBL] [Abstract][Full Text] [Related]
16. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
[TBL] [Abstract][Full Text] [Related]
17. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Wojtalla A; Fischer B; Kotelevets N; Mauri FA; Sobek J; Rehrauer H; Wotzkow C; Tschan MP; Seckl MJ; Zangemeister-Wittke U; Arcaro A
Clin Cancer Res; 2013 Jan; 19(1):96-105. PubMed ID: 23172887
[TBL] [Abstract][Full Text] [Related]
18. Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS.
Molinaro A; Becattini B; Mazzoli A; Bleve A; Radici L; Maxvall I; Sopasakis VR; Molinaro A; Bäckhed F; Solinas G
Cell Metab; 2019 Jun; 29(6):1400-1409.e5. PubMed ID: 30982732
[TBL] [Abstract][Full Text] [Related]
19. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
Williams O; Houseman BT; Kunkel EJ; Aizenstein B; Hoffman R; Knight ZA; Shokat KM
Chem Biol; 2010 Feb; 17(2):123-34. PubMed ID: 20189103
[TBL] [Abstract][Full Text] [Related]
20. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]